Prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%: value of the results of the FINEARTS-HF phase III randomized clinical trial (expert panel summary)
Yu. M. Lopatin,
S. N. Tereshchenko,
G. P. Arutyunov,
S. V. Villevalde,
A. S. Galyavich,
D. V. Duplyakov,
I. V. Zhirov,
N. E. Zvartau,
O. B. Irtyuga,
N. A. Koziolova,
S. V. Nedogoda,
I. V. Fomin,
S. S. Yakushin https://doi.org/10.15829/1560-4071-2026-6850
EDN: FTDPLM
Abstract
Heart failure with mildly reduced and preserved ejection fraction is a serious problem in modern healthcare due to its high prevalence, unfavorable prognosis, and significant limitations in optimal therapy. This article represents the resolution of an expert panel devoted to the prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%, based on the results of the FINEARTS-HF phase III randomized clinical trial. The data obtained demonstrate a high efficacy and safety profile for finerenone in this patient group, which rationales including this drug in widespread clinical practice for the treatment of symptomatic heart failure with a left ventricular ejection fraction ≥40% after registration of the appropriate indication.
Keywords
heart failure,
mildly reduced and preserved ejection fraction,
finerenone,
nonsteroidal mineralocorticoid receptor antagonists
Supporting agencies: The Expert Panel was held with the support of AO Bayer in December 2025.
About the Authors
Yu. M. Lopatin
Volgograd State Medical University
Russian Federation
Competing Interests:
Russian Federation
Fallen Fighters Square, 1, Volgograd
Competing Interests:
None
S. N. Tereshchenko
Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Academician Chazov str., 15A, Moscow, 121552
Competing Interests:
None
G. P. Arutyunov
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Ostrovityanova str., 1, bld. 6, Moscow, 117513
Competing Interests:
None
S. V. Villevalde
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
Akkuratov str., 2, St. Petersburg
Competing Interests:
None
A. S. Galyavich
Kazan State Medical University
Russian Federation
Competing Interests:
Russian Federation
49 Butlerova St., Kazan, Republic of Tatarstan, 420012
Competing Interests:
None
D. V. Duplyakov
Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Chapaevskaya str., 89, Samara, 443099
Competing Interests:
None
I. V. Zhirov
Chazov National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Academician Chazov str., 15A, Moscow, 121552
Competing Interests:
None
N. E. Zvartau
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
Akkuratov str., 2, St. Petersburg
Competing Interests:
None
O. B. Irtyuga
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
Akkuratov str., 2, St. Petersburg
Competing Interests:
None
N. A. Koziolova
Wagner Perm State Medical University
Russian Federation
Competing Interests:
Russian Federation
Petropavlovsk St., 26, Perm, 614000
Competing Interests:
None
S. V. Nedogoda
Volgograd State Medical University
Russian Federation
Competing Interests:
Russian Federation
Fallen Fighters Square, 1, Volgograd
Competing Interests:
None
I. V. Fomin
Privolzhsky Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Minina and Pozharsky Square, 10/1, Nizhny Novgorod, 603005
Competing Interests:
None
S. S. Yakushin
Ryazan State Medical University
Russian Federation
Competing Interests:
Russian Federation
Vysokovoltnaya str., 9, Ryazan, 390026
Competing Interests:
None
References
1. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev. 2023;9:e11. doi:10.15420/cfr.2023.05.
2. Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329(10):827-38. doi:10.1001/jama.2023.2020.
3. Bozkurt B, Ahmad T, Alexander KM, et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023;29(10):1412-51. doi:10.1016/j.cardfail.2023.07.006.
4. Vasan, R, Xanthakis, V, Lyass, A, et al. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. J Am Coll Cardiol Img. 2018;11(1):1-11. doi:10.1016/j.jcmg.2017.08.007.
5. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482-7. doi:10.1161/CIRCULATIONAHA.107.696906.
6. Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.). doi:10.15829/1560-4071-2024-6162. EDN: WKIDLJ.
7. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. doi:10.1093/eurheartj/ehad195.
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.
9. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063.
10. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475-85. doi:10.1056/NEJMoa2407107.
11. Vaduganathan M, Claggett BL, Lam CSP, et al. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail. 2024;26(6):1324-33. doi:10.1002/ejhf.3253.
12. Solomon SD, Ostrominski JW, Vaduganathan M, et al. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. Eur J Heart Fail. 2024;26(6):1334-46. doi:10.1002/ejhf.3266.
13. Desai AS, Vaduganathan M, Claggett BL, et al. Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. J Am Coll Cardiol. 2025;85(2):106-16. doi:10.1016/j.jacc.2024.09.004.
14. Docherty KF, Henderson AD, Jhund PS, et al. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. 2025;151(1):45-58. doi:10.1161/CIRCULATIONAHA.124.072011.
15. Mc Causland FR, Vaduganathan M, Claggett BL, et al. Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial. J Am Coll Cardiol. 2025;85(2):159-68. doi:10.1016/j.jacc.2024.10.091.
16. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84. doi:10.1093/eurheartj/ehab777.
17. Levey AS, Grams ME, Inker LA. Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease. N Engl J Med. 2022;386(22):2120-28. doi:10.1056/NEJMra2201153.
18. Vaduganathan M, Claggett BL, Desai AS, et al. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025;10(2):176-81. doi:10.1001/jamacardio.2024.3782.
19. Vaduganathan M, Claggett BL, Kulac IJ, et al. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 2025; 151(2):149-58. doi:10.1161/CIRCULATIONAHA.124.072055.
20. Agarwal R, Green JB, Heerspink HJL, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-43. doi:10.1056/NEJMoa2410659.
21. Matsumoto S, Jhund PS, Henderson AD, et al. Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF. J Am Coll Cardiol. 2025;85(2):173-85. doi:10.1016/j.jacc.2024.11.020.
22. Rastogi T, Ferreira JP, Butler J, et al. Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved. Eur J Heart Fail. 2024;26(4):885-96. doi:10.1002/ejhf.3136.
23. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S): S117-S314. doi:10.1016/j.kint.2023.10.018.
24. Bobkova IN. The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review. Terapevticheskii Arkhiv. 2023;95(9):796-801. (In Russ.) doi:10.26442/00403660.2023.09.202367. EDN: FXWDUG.
25. Kolkhof P, Jaisser F, Kim SY, et al. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handb Exp Pharmacol. 2017;243:271-305. doi:10.1007/164_2016_76.
26. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-61. doi:10.1093/eurheartj/ehaa736.
27. Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity. Hypertension. 2018;71(4):599-608. doi:10.1161/HYPERTENSIONAHA.117.10360.
28. Yu J, Zhou G, Guo Y, Long Y. Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies. CVIA. 2025;10(1). doi:10.15212/CVIA.2024.0050.
29. Daou D, Gillette TG, Hill JA. Inflammatory Mechanisms in Heart Failure with Preserved Ejection Fraction. Physiology (Bethesda). 2023;38(5):0. doi:10.1152/physiol.00004.2023.
30. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. doi:10.1056/NEJMoa1313731.
31. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42. doi:10.1161/CIRCULATIONAHA.114.013255.
32. Anand IS, Claggett B, Liu J, et al. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. JACC Heart Fail. 2017;5(4):241-52. doi:10.1016/j.jchf.2016.11.015.
33. Szabo B, Benson L, Savarese G, et al. Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction — a secondary analysis of TOPCAT. Am Heart J. 2024;271:136-47. doi:10.1016/j.ahj.2024.02.021.
34. Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-62. doi:10.1093/eurheartj/ehv464.
35. Merrill M, Sweitzer NK, Lindenfeld J, Kao DP. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. JACC Heart Fail. 2019;7(3):228-38. doi:10.1016/j.jchf.2019.01.003.
36. Chimura M, Wang X, Jhund PS, et al. Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025;10(1):59-70. doi:10.1001/jamacardio.2024.4613.
37. Cunningham JW, Claggett BL, Vaduganathan M, et al. Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. Eur J Heart Fail. 2025;27(8):1487-91. doi:10.1002/ejhf.3694.
38. Richard EL, Desai NR, Willey VJ, et al. Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS). Pragmat Obs Res. 2025;16:27-37. doi:10.2147/POR.S489791.
39. Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173-84. doi:10.1093/eurjhf/hft134.
40. Trevisan M, Fu EL, Xu Y, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23(10):1698-707. doi:10.1002/ejhf.2287.
41. Shlyakhto EV, Belenkov YuN, Boytsov SA, et al. Use of guideline-directed medical therapy in outpatients with heart failure in real-world practice: a subanalysis of PRIORITY-HF study. Russian Journal of Cardiology. 2025;30(11S):6517. (In Russ.) doi:10.15829/1560-4071-2025-6517. EDN: WFHVQR.
42. Vardeny O, Vaduganathan M, Claggett BL, et al. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025;10(1):42-8. doi:10.1001/jamacardio.2024.4539.
43. Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758-64. doi:10.1038/s41591-024-03264-4.
Review
For citations:
Lopatin Yu.M., Tereshchenko S.N., Arutyunov G.P., Villevalde S.V., Galyavich A.S., Duplyakov D.V., Zhirov I.V., Zvartau N.E., Irtyuga O.B., Koziolova N.A., Nedogoda S.V., Fomin I.V., Yakushin S.S. Prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%: value of the results of the FINEARTS-HF phase III randomized clinical trial (expert panel summary). Russian Journal of Cardiology. 2026;31(3):6850. (In Russ.) https://doi.org/10.15829/1560-4071-2026-6850. EDN: FTDPLM
Views:
131
JATS XML
Email this article 